Repositioning Candidate Details
| Candidate ID: | R0207 |
| Source ID: | DB00713 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Oxacillin |
| Synonyms: | |
| Molecular Formula: | C19H19N3O5S |
| SMILES: | [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O |
| Structure: |
|
| DrugBank Description: | An antibiotic similar to flucloxacillin used in resistant staphylococci infections. |
| CAS Number: | 66-79-5 |
| Molecular Weight: | 401.436 |
| DrugBank Indication: | Used in the treatment of resistant staphylococci infections. |
| DrugBank Pharmacology: | Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. |
| DrugBank MoA: | By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor. |
| Targets: | Penicillin-binding protein 3; Penicillin-binding protein 2a; Penicillin-binding protein 1A; Penicillin-binding protein 2B; Penicillin-binding protein 1b; Penicillin-binding protein 1A; Solute carrier family 15 member 1; Penicillin-binding protein 2; Solute carrier family 15 member 2; Beta-lactamase Toho-1 |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |